SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Astellas and Audax Biosciences Enter Exclusive Option and License Agreement

The agreement covers DAX-044, an immune-targeted IL-12 antibody-cytokine fusion for immuno-oncology.

Related stories